Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection

Table 2 Comparison of AZ versus placebo on microbiome outcomes between baseline and week 3

Median (distribution free 95% confidence limits) [p-value¹]		Azithromycin (N = 101)	Placebo (N = 97)	p-value²
TBL	Baseline	6.0 (5.9, 6.1)	6.1 (6.0, 6.3)	0.13
	Change from baseline to week 3	-0.3 (-0.5, -0.2) [p < 0.01]	-0.4 (-0.5, -0.2) [p < 0.01]	0.72
SDI	Baseline	3.3 (3.0, 3.4)	3.5 (3.4, 3.6)	0.12
	Change from baseline to week 3	-0.8 (-1.1, -0.5) [p < 0.01]	-0.6 (-0.9, -0.4) [p < 0.01]	0.16

¹ p-value assessing whether change from baseline is different from 0 using signed rank test
² p-value testing AZ versus placebo group from Wilcoxon test
TBL = Total Bacterial Load (log₁₀ rRNA copy number), SDI = Shannon Diversity Index

ISSN: 1471-2180